The correlation between a higher percentage of Vim+, CD80+, and CD155+ cancer cells and a higher risk of progression/relapse was not significant in all cohorts (Fig. 7o), but a trend was observed that should be validated with a larger number of patient samples. Here, VIM is linked to cancer.